All In Biotech

Drug Trial Radar · NCT06681493

A Phase 1 Study of YZJ-4729 Tartrate Injection in Healthy Chinese Subjects

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and PK/PD of YZJ-4729 Tartrate Injection After A Single Ascending Dose

Last checked: Nov 20, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Oct 12, 2022

Primary completion

Apr 14, 2023

Study completion Sep 22, 2023

Sponsor

Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Part A Primary objective: • To evaluate the safety, tolerability, and pharmacokinetic profile of a single dose of YZJ-4729 tartrate injection. Secondary objectives: * To investigate the PK/PD profile of YZJ-4729 tartrate injection administered as a single dose; * To investigate the metabolic transformation characteristics of YZJ-4729 tartrate; * To assess the relationship between plasma concentrations and change in QT interval (C-QT) and the effect on QT interval in subjects after a single dose of YZJ-4729 tartrate injection. Part B Primary objective: • To evaluate the safety, tolerability and pharmacokinetic profile of YZJ-4729 tartrate injection administered at the same dose and at different infusion rates . Secondary objectives: • To investigate the PK/PD profile of YZJ-4729 tartrate injection administered at the same dose and at different infusion rates.

Conditions

  • Postoperative Analgesia

Interventions

  • YZJ-4729 Tartrate injectionDrug

    Infusion, QD

  • YZJ-4729 simulated injectionDrug

    Infusion, QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: Part A: From Day 1 to Day 5 Part B: From Day 1 to Day 17
  2. Incidence of participants with clinical laboratory abnormalitiesTime frame: Part A: From Day 1 to Day 5 Part B: From Day 1 to Day 17
  3. Incidence of participants with vital signs abnormalitiesTime frame: Part A: From Day 1 to Day 5 Part B: From Day 1 to Day 17
  4. Incidence of participants with physical exam abnormalitiesTime frame: Part A: From Day 1 to Day 5 Part B: From Day 1 to Day 17
  5. CmaxTime frame: Pre-dose to 72 hours post-dose
  6. AUCinfTime frame: Pre-dose to 72 hours post-dose
  7. AUC0-24hTime frame: Pre-dose to 72 hours post-dose
  8. AUC0-tTime frame: Pre-dose to 72 hours post-dose
  9. t1/2zTime frame: Pre-dose to 72 hours post-dose
  10. TmaxTime frame: Pre-dose to 72 hours post-dose
  11. CLTime frame: Pre-dose to 72 hours post-dose
  12. VzTime frame: Pre-dose to 72 hours post-dose
  13. MRTTime frame: Pre-dose to 72 hours post-dose
  14. Ae0-tTime frame: Pre-dose to 72 hours post-dose
  15. Cumulative excretion percentage of drug through urine and fecesTime frame: Pre-dose to 72 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xiangya Third Hospital, Central South University

    Changsha, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.